In trials, less than half of vaccine recipients reported moderate or severe episodes of side effects such as fever, headache and fatigue. Photo: Sina Schuldt/dpa
In trials, less than half of vaccine recipients reported moderate or severe episodes of side effects such as fever, headache and fatigue. Photo: Sina Schuldt/dpa

The European Medicines Agency (EMA) began evaluating the use of the Moderna coronavirus vaccine for adolescents between 12 and 17 years old and expects the results of the study to be available in July.

“EMA has started evaluating an application to extend the use of the COVID-19 Vaccine Moderna to include young people aged 12 to 17,” the regulator said in a statement.

According to the EMA, the regulator’s human medicines committee will now carry out an accelerated assessment of clinical study data submitted in the application, after which the results will be forwarded to the European Commission for final decision.

The outcome of the evaluation is expected to be released in July, unless supplementary information is needed, the EMA added.

Currently, Moderna is authorized for use in people aged 18 and older.

Disclaimer: News Ghana is not responsible for the reportage or opinions of contributors published on the website.

Send your news stories to [email protected] and via WhatsApp on +1-508-812-0505 

Previous articlePalestine Files 3 Lawsuits Against Israel With ICC
Next articleHundreds of Military Personnel to Ensure Safety at G7 Summit in England

LEAVE A REPLY

Please enter your comment!
Please enter your name here